Date of event
Wednesday, May 19, 2021 - 11:00 am -
Wednesday, May 19, 2021 - 12:00 pm
Continuing Education Credits
None
Add to Calendar 2021-05-19 11:00:00 2021-05-19 12:00:00 Webinar: Challenges in NASH Clinical Trials AASLD alonzo.tolver@boldrstrategy.com America/New_York public

Content Contributor

Nonalcoholic Fatty Liver Diseases SIG

Presenters

  • Naim Alkhouri, MD
  • Manal F. Abdelmalek, MD, MPH, FAASLD
  • Mazen Noureddin, MD

Moderators

  • Vlad Ratziu, MD

Details

Join the Nonalcoholic Fatty Liver Disease Special Interest Group in discussing the current challenges in histological assessment in NASH clinical trials. Presenters will also discuss how to implement hard outcomes in NASH clinical trials and the use non-invasive biomarkers as primary endpoints for drug approval.


 

Presenters Bios

Naim Alkhouri, MD

Naim Alkhouri, MD is the Vice President of Academic Affairs, Chief of Transplant Hepatology and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatric at the University of Texas (UT) Health in San Antonio, TX. Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute.

Dr. Alkhouri has been published in over 160 publications and presents his work at both national and international medical conferences. Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease. Dr. Alkhouri's specialty interests include nonalcoholic fatty liver disease, metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency and liver transplantation.

Photo of Dr. Naim Alkhouri


 

Manal F. Abdelmalek, MD, MPH, FACP, FACG, FAASLD

Manal F. Abdelmalek, MD, MPH, FAASLD is tenured professor of medicine in the Division of Gastroenterology and Hepatology and director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University. Since first reporting on nonalcoholic steatohepatitis (NASH) as a cause of cryptogenic cirrhosis nearly 25 years ago, her clinical and research area of interest has focused on NAFLD / NASH, associated risk factors for disease acquisition and progression and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials, including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH. 

Dr. Abdelmalek collaborates extensively to translate new compounds to first-in-man clinical studies and translate clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression. She is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/ consultant to many industries, FDA and biomarker development companies in diagnostics and therapeutics for NASH.  She is the lead Principal Investigator on several multicenter global studies, a member of the AASLD Global Outreach and Engagement Committee and past member of the AASLD Clinical Research Committee.  As a teacher and educator, she has mentored clinical residents, fellows, faculty at rank of assistant / associate professor from Duke University as well as other institutions in the study and research of liver disease.  Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease. She is a standing member of NASH Clinical Research Network (NASH CRN) for the past 15 years. Dr. Abdelmalek has published more than 200 manuscripts and currently serves on the Editorial Board of HEPATOLOGY, the official journal of the AASLD. 

Photo of Dr. Manal F. Abdelmalek


 

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center (currently ranked #2 in GI and GI surgery per US News). His focus is on clinical and translational research in the area of NAFLD/NASH. Dr. Noureddin has conducted more than 35 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques.

Dr. Noureddin has published in all these areas. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. He is the chair of the AASLD NASH special interest group education sub-committee and serves on the editorial board for the journals “Clinical Gastroenterology and Hepatology (CGH)” and “Gastroenterology”. He is funded by the National Cancer Institute.

Photo of Dr. Mazen Noureddin


 

Moderator Bios

Vlad Ratziu, MD, PhD

Vlad Ratziu, MD, PhD is a professor of hepatology at Sorbonne University, and performs his hospital work at the Pitié-Salpêtrière Hospital and the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, France. Professor Ratziu received his medical training at Paris Descartes University; he then completed a two-year postdoctoral fellowship at the Liver Center at the University of California, San Francisco, CA, USA, and went on to earn a doctoral degree from Paris Diderot University for his work on the pathophysiology of viral and metabolic liver fibrosis.

Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia. He is

a member of the organising committee of the NASH–TAG meetings. He is a co-editor for the Journal of Hepatology and an associate editor for Clinical Liver Disease. He has published more than 300 articles in top-tier specialty journals.

Photo of Dr. Vlad Ratziu